mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / ...
(Bloomberg) -- Moderna Inc.’s shares fell after US regulators refused to review its novel mRNA flu vaccine, creating regulatory chaos for the pharmaceutical industry and offering another example of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results